Last reviewed · How we verify
A Phase I Study of BR108 in Hematological Malignancies
A Phase I study of BR108 in hematological malignancies
Details
| Lead sponsor | BioRay Pharmaceutical Co., Ltd. |
|---|---|
| Phase | PHASE1 |
| Status | TERMINATED |
| Enrolment | 8 |
| Start date | Sat Mar 18 2023 00:00:00 GMT+0000 (Coordinated Universal Time) |
| Completion | Fri Jun 21 2024 00:00:00 GMT+0000 (Coordinated Universal Time) |
Conditions
- Hematologic Malignancy
Interventions
- BR108 injection
Countries
China